RVX CommunicationsRecently an article was published with the following title;
ACC: PCSK9 Inhibitors May Halve Hear Event Risk
- Novel lipid lowering drugs suggest big benefit in exploratory trial analysis.
by Crystal Phend
Senior Staff Writer, MedPage
SAN DIEGO - - The dramatic LDL cholesterol-lowering impact of novel PCSK9 inhibitors appeared to pay our in big cardiovascular risk reduction, according to post hoc analysis, which offered an early look at what big outcomes trials will show.
---------------------------------------------------------
Now replace that with the following;
RVX: RVX-208, An Epigenetic BET-Bromodomain Inhibitor May Reduce Heart Event Risk By Over 75%
- Novel epigenetic ApoA-l increasing drug suggests big benefits in reducing major cardiac events in combined trial analysis.
by author
Title
SAN FRANCISCO - The dramatic ApoA-l increasing epigenetic BET-Bromodomain inhibiting drug rvx-208 appears to pay out big in cardiovascular risk reduction according to......... Post hoc analysis of the combined ASSURE/SUSTAIN trials demonstrated a 77% reduction (p=.01) in the large and growing population of patients with diabetes mellitus and cardiovascular disease. As obesity continues to rise rapidly in America diabetes mellitus and cardiovascular disease continue to rise with it. rvx-208 is a novel selective BET Bromodomain dug developed by Resverlogix Corporation over a 10 year period is now moving into a phase 3 trial to verify it's dramatic impact in reducting cardiovascular events. Reductions in MACE started early in the trial (evident at day 15) and continued through the 210 day trial.
-----------------------------------------------------
Publish something like this (obviously not written by me but by a professional writer) in the business section and health and lifestyle sections of all major newspapers and we see some share action.
If anyone one has any idea to help RVX become effective communicators PLEASE LET THEM KNOW. THEY DESPARATELY NEED HELP and by implication, so do we.
IMHO
Happy spring!
Toinv :)